Vaxcyte, Inc. (PCVX)
Largest Insider Buys in Sector
PCVX Stock Price History Chart
PCVX Stock Performance
About Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine …
Insider Activity of Vaxcyte, Inc.
Over the last 12 months, insiders at Vaxcyte, Inc. have bought $0 and sold $58.05M worth of Vaxcyte, Inc. stock.
On average, over the past 5 years, insiders at Vaxcyte, Inc. have bought $41.38M and sold $35.29M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 186,000 shares for transaction amount of $2.98M was made by Hopfner Robert Lorne (director) on 2020‑06‑16.
List of Insider Buy and Sell Transactions, Vaxcyte, Inc.
| 2024-11-05 | Sale | SVP, GEN COUNSEL & CORP SEC | 5,000 0.0041% | $106.36 | $531,803 | -2.57% | ||
| 2024-11-01 | Sale | CHIEF EXECUTIVE OFFICER | 15,000 0.0123% | $106.82 | $1.6M | -0.75% | ||
| 2024-11-01 | Sale | CHIEF OPERATING OFFICER | 8,000 0.0065% | $106.80 | $854,423 | -0.75% | ||
| 2024-10-18 | Sale | PRESIDENT AND CFO | 42,000 0.0344% | $115.39 | $4.85M | -7.86% | ||
| 2024-10-07 | Sale | CHIEF EXECUTIVE OFFICER | 7,098 0.0057% | $109.21 | $775,154 | +3.14% | ||
| 2024-10-07 | Sale | SVP, GEN COUNSEL & CORP SEC | 5,000 0.004% | $109.27 | $546,353 | +3.14% | ||
| 2024-10-01 | Sale | CHIEF EXECUTIVE OFFICER | 55,000 0.0463% | $114.25 | $6.28M | -3.28% | ||
| 2024-10-01 | Sale | CHIEF EXECUTIVE OFFICER | 50,712 0.0427% | $114.19 | $5.79M | -3.28% | ||
| 2024-10-01 | Sale | CHIEF OPERATING OFFICER | 8,000 0.0067% | $114.24 | $913,917 | -3.28% | ||
| 2024-10-01 | Sale | SVP, GEN COUNSEL & CORP SEC | 5,500 0.0046% | $114.24 | $628,295 | -3.28% | ||
| 2024-09-18 | Sale | PRESIDENT AND CFO | 8,000 0.0065% | $115.94 | $927,551 | -2.94% | ||
| 2024-09-17 | Sale | director | 6,250 0.0051% | $116.28 | $726,731 | -3.10% | ||
| 2024-09-16 | Sale | CHIEF OPERATING OFFICER | 10,000 0.0083% | $115.96 | $1.16M | -0.96% | ||
| 2024-09-03 | Sale | CHIEF OPERATING OFFICER | 10,000 0.0091% | $111.93 | $1.12M | +3.61% | ||
| 2024-09-03 | Sale | SVP, GEN COUNSEL & CORP SEC | 1,667 0.0015% | $112.11 | $186,880 | +3.61% | ||
| 2024-09-03 | Sale | SVP, FINANCE | 5,000 0.0044% | $107.67 | $538,350 | +3.61% | ||
| 2024-08-23 | Sale | CHIEF EXECUTIVE OFFICER | 15,000 0.0134% | $78.98 | $1.18M | +41.29% | ||
| 2024-08-19 | Sale | PRESIDENT AND CFO | 8,000 0.0071% | $78.58 | $628,650 | +41.55% | ||
| 2024-08-01 | Sale | CHIEF OPERATING OFFICER | 3,000 0.0028% | $78.84 | $236,527 | +41.61% | ||
| 2024-08-01 | Sale | CHIEF EXECUTIVE OFFICER | 2,616 0.0024% | $78.79 | $206,122 | +41.61% |
Insider Historical Profitability
| TPG Group Holdings (SBS) Advisors, Inc. | 5074574 4.1662% | $103.63 | 1 | 1 | <0.0001% | |
| EMSTER KURT VON | director | 4168718 3.4225% | $103.63 | 1 | 0 | <0.0001% |
| Heron Patrick J | director | 2309554 1.8961% | $103.63 | 1 | 0 | <0.0001% |
| Hopfner Robert Lorne | director | 1405418 1.1538% | $103.63 | 1 | 21 | <0.0001% |
Institutional Investor Ownership
| Fidelity Investments | $1.11B | 14.95 | 16.26M | +14.41% | +$139.88M | 0.07 | |
| The Vanguard Group | $665.15M | 8.95 | 9.74M | +15.2% | +$87.77M | 0.01 | |
| BlackRock | $649.83M | 8.74 | 9.51M | +10.93% | +$64.02M | 0.01 | |
| RA Capital Management, L.P. | $560.4M | 7.54 | 8.2M | +3.96% | +$21.35M | 0.56 | |
| Janus Henderson | $524.12M | 7.05 | 7.67M | +9.92% | +$47.3M | 0.26 |